pharmaceutical-analytics-insights-Sci Forschen

Full Text

Development and Validation of New Analytical Methods for the Simultaneous Estimation of Levamisole and Albendazole in Bulk and Tablet Dosage Form by RP-HPLC

  Santhosh Kumar Ettaboina1       Komalatha Nakkala2*   

1Analytical Research and Development, Aurex Laboratories Pvt. Ltd. Kukatpally, Hyderabad, Telangana-500072, India
2Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra-400019, India

*Corresponding author: Nakkala K, Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra-400019, India, E-mail:


A reverse-phase high-performance liquid chromatographic (RP-HPLC) method was developed to analyze levamisole and albendazole in tablet dosage forms. This method was simple, robust, and rapid reverse-phase high-performance liquid chromatography for the separation and quantitative determination of the Levamisole & Albendazole in combination forms. The victorious separation was achieved on Inertsil C18 (4.6 × 250mm, 5µm) Column, using Isocratic elution. The mobile phase contains 0.02M phosphate buffer (pH 3.0) and methanol in a ratio of (30:70v/v). The flow rate was monitored at 1.0 mL min-1 throughout the analysis and detection and quantitation of the main active pharmaceutical ingredients were achieved using a PDA detector at 220nm. The proposed method was validated according to the current ICH guidelines for specificity, linearity, accuracy, precision, ruggedness, and robustness. The proposed method was showed a linear response (R2 >0.999), accurate (recoveries 97-103%), precise (RS ≤ 1.0%), sensitive and specific. The anticipated reverse phase-liquid chromatography method was successfully helpful for the routine analysis of drugs in pharmaceutical dosage forms.


HPLC; Levamisole; Albendazole; Method development; Validation


HPLC: High-performance liquid chromatography; ICH: International conference on harmonization; ALB: Albendazole; LEV: Levamisole; LOD: Limit of detection; LOQ: Limit of quantification; Rt: Retention time; RSD: Relative Standard Deviation

Graphical Abstract

APIs-Active Pharmaceutical Ingredients; BCSBiopharmaceutical Classification System; COPD–Chronic Obstructive Pulmonary Disease; DNA- Deoxyribonucleic Acid; GI-Gastrointestinal Track; HPH-High Pressure Homogenization; ICH-International Conference on Harmonization; LED-Light-Emitting Diode; PS-Particle Size; PSD-Particle Size Distribution; PGP-P-Glycoprotein; USPUnited States Pharmacopeia


Levamisole is an anti-helminthic medication [1] widely used in the treatment of infections caused by viral [2], bacterial [3], and also recently reported for covid-19 treatment [4]. It is chemically known as (6S)-6-phenyl-2H,3H,5H,6H-imidazo [2,1-b] [1,3] thiazole. It was manufactured by Janssen and used as an agent for treating worm infestations in 1969; Levamisole was approved as an adjuvant treatment for colon cancer by the FDA in 1990. Before this, levamisole was used as an antirheumatic therapy [5] for patients with rheumatoid arthritis. It shows immunomodulatory effects [6-9]; this drug was studied to treat various immune-mediated diseases; this drug was also used in combination with other drugs to treat various cancers. Levamisole was used in both humans and animals as an anthelmintic to treat worm infections. Levamisole acts as a nicotinic receptor agonist, which leads to paralysis of parasitic worms through continuous stimulation of their muscles. Levamisole has been used to treat many dermatological conditions, including skin infections, leprosy, warts, lichen planus, and aphthous ulcers. Levamisole drug is official in Indian Pharmacopoeia [10], European Pharmacopoeia [11], British Pharmacopoeia [12], and United States Pharmacopoeia [13].

Albendazole, also known as albendazolam, is a medication used to treat various parasitic worm infestations. It is used to treat giardiasis, trichuriasis, fil, neurocysticercosis, hydatid, pinworm and ascariasis. It is chemically known asmethyl N-[6-(propylsulfanyl)-1H-1,3- benzodiazol-2-yl] carbamate.

Albendazole drug is official in British Pharmacopoeia [14], European Pharmacopoeia [15], and United States Pharmacopoeia [16].

Albendazole and Levamisole combination was used to treat worm infections in humans. Albendazole works by preventing sugar (glucose) in consumed worms, so they lose their energy and die. Levamisole treats worm infections by decreasing the function of the muscles and causing the worms to become paralyzed. The chemical structures of Levamisole and Albendazole were shown below in (Figure 1).

Figure 1: Chemical Structures of Levamisole and Albendazole.

Several analytical methods were reported to determine the ALB or LEV either individually or in other pharmaceuticals. Previous reported methods were described the use of GC-MS [17,18], LC-MS [19-24], UPLC [25,26], and HPLC [27-35].

Materials and Methods
Chemicals and reagents

All reagents used were analytical grade, and solvents used were HPLC grade; Methanol (JT beaker) with a certified purity of 99.9% was purchased from Avantor performance materials, LLC, Radnor, PA, USA. The orthophosphoric acid was procured from Macron chemicals, USA. High-quality In-House purity water was used for the experiments (TOC<500ppb, pH about 7.0, Conductivity <1.0µs/ cm, finally exposed to UV radiation and followed filtered through 0.2µm filter). Albendazole was (100% pure) procured from MSN Laboratories Pvt Ltd. Hyderabad, India. Levamisole (100% pure) was procured from Shaanxi Hanjiang Pharmaceutical Group Co. China.

Instrumentation and software

Waters HPLC system Alliance e2695 separation module with an auto-injector, temperature controller for sample storage, and Empower 3 Software Build 3471 SPs were used to monitor the signal output. Feature Release 3 DB ID: 2639633283 has been installed. The LC column is made of Inertsil C18 (250mm × 4.6 mm) 5µm. It is manufactured by GL Sciences Inc. Analytical balance model CP225D (make: Sartorius), Top load balance model GP5202 (make: Sartorius) sonicator (make: LIFECARE), pH Meter (make: ORION 3 STAR), Thermal oven (make: NEWTRONIC) were employed in this work.

Chromatographic conditions

The chromatographic separation was achieved by using the LC Inertsil C18 column (250mm × 4.6mm 5µm) with 0.02 M phosphate buffer (pH 3.0) and methanol in the ratio of 30:70 (v/v) was used as mobile phase. The mobile phase was filtered through a 0.22µm filter, and the flow rate was 1.0mL.min-1 with a isocratic elution method. Detection and quantitation of the main active pharmaceutical ingredients were achieved using a PDA detector at 220 nm with an injection volume of 10μL.

Standard preparation

A standard stock solution, Levamisole & Albendazole (1000μg. mL−1), was prepared by dissolving LEV, ALB (100mg), to make 100mL of solution in the mobile phase. Pipette out 10.0 mL of standard stock supernatant solution into 100mL volumetric flask and dilute to volume with diluent and mix well. The system suitability, results and evaluation were shown in table 1, and the standard chromatogram was illustrated in (Figure 2).

Figure 2: Dilute Standard of Albendazole and Levamisole.

Publication Title & Reference Chromatographic Conditions


Development of RP-HPLC Method for the Simultaneous Quantitation of Levamisole and Albendazole: Application to Assay Validation [34] Mobile phase: Buffer of pH 3.5 and Acetonitrile (70:30 v/v)
Column: Inertsil ODS C18 (4.6 × 150 mm, 5µm)
Flow rate: 1.0 mL/min
Detector: 224nm
Injection volume: 20µL
Column temperature: 25°C
  1. The concentration of the sample is deficient and challenging to extract the subject sample at 30µg mL and 80µg mL of LEV+ALB
  2. Responses of Levamisole and albendazole is too low
  3. Broad peak shape of active compounds
Stability indicating method development and validation for simultaneous estimation of Levamisole HCl and albendazole in tablet dosage form [37] Mobile phase: Phosphate Buffer pH 5.0:
Acetonitrile (30:70 % v/v)
Column: Shiseido C18 (250 mm × 4.6 mm, 5μm)
Flow rate: 1.0mL/min
Detector: 217nm
Injection volume: 20µL
Column temperature: 25°C
  1. The concentration of the sample is deficient, and difficult to extract the subject sample at 7.5µg mL and 20µg mL of LEV+ALB
  2. Responses of Levamisole and albendazole is too low
Current Proposed Method
A rapid, simple, specific, reproducible, and robust reversed-phase HPLC method was developed and validated per ICH guidelines for the determination of Albendazole and Levamisole in bulk and tablet dosage form. Both albendazole and levamisole were detected within 5 minutes of run time using the Inertsil C18 (4.6 × 250mm, 5µm) column. With simple isocratic mobile phase contains 0.02M phosphate buffer (pH 3.0) and methanol in a ratio of 30:70(v/v). The flow rate is 1.0 mL min-1, and the injection volume is 10µl. Detection was at 220nm.

Table 1: Comparison of published LC method conditions.

Sample preparation

Accurately weighed ten tablets, crushed in a mortar and pestle, then equivalent to 100mg of Albendazole and Levamisole (marketed formulation) samples were transferred into a 100mL clean, dry volumetric flask, then 70mL of mobile phase was added and the mixture was sonicated for 20 min with occasional shaking. The mixture was then allowed to cool down to room temperature, diluted to volume with a mobile phase to get the concentration of 1000µg/ mL and it was used for further analysis. 10mL of supernatant was withdrawn from the stock solution, transferred in 100mL volumetric flask, diluted to volume with a mobile phase mixed well.

Results and Discussion
Method development strategy and optimization

The previous literature was assessed, concludes the report, and discussed in table 2. To provide a suitable procedure for the routine quality control analysis of this multi-component drug mixture. The liquid chromatographic method coupled with diode array detection. The developed process was carefully designed and optimized to separate the cited compounds. The most critical aspect in LC method development is the achievement of sufficient resolution of the analytes with good peak symmetry in a reasonable analysis time. Many experiments were carried out to optimize both the stationary and mobile phases for better results. In these trials, evaluation was based on efficient resolution between the two analytes peaks. For optimization of the stationary phase, different types of columns were tested entirely, such as Thermo Hypersil BDS C8 (4.6 × 150mm), Durashell-C18 (4.6 × 250mm), Venusil XBP CN (4.6 × 250mm), and Inertsil C18 (250mm × 4.6mm) 5µm. The most desirable clear separation between the two primary compounds within a relatively short run time was obtained using the Inertsil C18 (250mm × 4.6mm) 5µm column; consequently, it became the column of choice for this mixture. Other columns exhibited poor separation between the peaks of the target compounds. Some other trials revealed insufficient resolution between ALB and LEV. The excessive tailing for the peaks was another disadvantage of using the Thermo Hypersil BDS, Durashell-C18, and Venusil XBP CN columns.

Compound USP Tailing RT USP Plate Count Resolution % RSD
Albendazole 1.13 2.34 5643 NA 0.8
Levamisole 1.22 3.16 7564 3.5 0.5

Table 2: System suitability evaluation.
RT-Retention time; RSD-Relative standard deviation

The multi-wavelength ranges were evaluated to measure each analyte at its maximum wavelength to verify the sensitivity. ALB and LEV show stronger UV absorption with prominent peaks at 220nm.

Further optimization was carried eluting peaks with optimal separation by varying the flow rates (0.5 mL/min to 1.0 mL/min) and column temperature (range from 25°C to 40°C).

Estimation of Levamisole & Albendazole in different mobile phases, solvent-buffer ratios were tried to proposed final chromatographic conditions. The shape of the peaks, the symmetry, and resolution of Levamisole & Albendazole were good with mobile phase contains 0.02M phosphate buffer (pH 3.0) and methanol in a ratio of (30:70v/v). Isocratic elution at a 1.0mL/min flow rate, sample, and column temperature was maintained at 25°C. The developed method was successfully helpful to estimate the amount of Levamisole & Albendazole in bulk and tablet dosage form.

Method validation

Analytical method validation is essential to ensure that the analytical procedure employed for a specific test is appropriate for its intended. After method development, analytical techniques were validated before the duration of routine use. The parameters evaluated during contemporary method development include specificity, linearity, range, accuracy, robustness, & precision.

The proposed method was validated based on the International Conference on Harmonization (ICH) Q2 (R1) guidelines [36,37].


An essential obligatory ICH guideline for method validation is specificity or selectivity. In other words, specificity is the capability to evaluate the purity of the analyte in the being there of the co-eluting or co-migrating impurity. The method specificity was illustrated by demonstrating that no excipients interfere with the retention time of both drugs in the assay sample chromatogram.

Method precision

In method precision, a homogenous test of a single batch was analyzed six times. The results determine whether a method produces consistent results for a single batch. Calculate the average results (X), standard deviation (SD), and the percent relative standard deviation (%RSD). The proposed method was found to be precise since the RSD values method precision was below 1.0. The summary results were shown in table 3.

Parameters Albendazole Levamisole
Range (µg mL-1) 10-150 10-150
Slope 10956.22 9380.96
Intercept 6173.49 4452.59
Correlation Coefficient 0.999 0.999
STYX SD 9679.18 6666.72
LOD (µg/mL-1) 4.2 3.8
LOQ (µg/mL-1) 14.3 16.5
Accuracy(a)(% of Recovery)    
50% Mean ± SD 100.3 ± 0.38 99.5 ± 1.15
100% Mean ± SD 100.4 ± 0.15 100.1 ± 0.21
150% Mean ± SD 101.0 ± 0.61 99.8 ± 0.67
Repeatability 0.9 0.5
Intermediate precision 1.1 1
95% Confidence interval 99.825, 100.775 100.540, 101.460

Table 3: Method validation results.
(a)Average of three determinations of each concentration level.
(b)% RSD of six determinations of each component.

LOD (Limits of Detection) and LOQ (Limits of Quantification)

The LOQ and LOD are calculated using signal-to-noise ratios at analytical responses of 3×10 times the background noise. The method validation results were shown in table 3.

LOD (mg/L) =3 ×Noise/signal × Lowest concentration of the linearity samples

LOD (mg/L) =10 ×Noise/signal × Lowest concentration of the linearity samples


An assay can obtain test results directly proportional to the concentration of an analyte in the sample. The determination of this parameter will define the range of the analytical assay. The linearity of the method was determined by drawing the calibration curves. Standard solutions of Levamisole & Albendazole of different concentrations levels (10%-150%) prepared by serial dilution of standard stock solution) were used for this purpose. The summary results were presented in table 3, and linearity curve was shown in (Figure 3).

Figure 3: Dilute Standard of Albendazole and Levamisole.


The accuracy of an analytical method is the closeness of the test results obtained by the process to the actual value. Accuracy may often be expressed as a percent of recovery by testing known added amounts of analyte. Accuracy was the measurement of the exactness of the analytical method.

In this HPLC method, the recovery of the samples was verified with three concentration levels (50%, 100% & 150%). The recovery was performed by API + placebo and injected into the HPLC (triplicate). The summary results were presented in table 3.


To demonstrate the robustness of the method, changes were made to the chromatographic conditions and system suitability parameters, such as tailing factor (<2.0), theoretical plate counts (>3000), and resolutions were between the nearest peaks (>2.0). Based on the results, the optimized method was proved robust, even under changed conditions. The summary results were presented in table 4.

Parameter Albendazole Levamesole Resolution b/w ALB
Retention Time USP Tailing USP Plate Count Retention Time USP Tailing USP Plate Count
Normal 2.3 1.2 5512 3.2 1.1 7423 3.4
Low Flow (0.8mL/min) 2.6 1.1 5342 3.5 1.2 7564 3.6
High Flow (1.2 mL/min) 2.05 1 5453 2.95 1.3 7012 2.9
High Temperature (30ºC) 2.2 1.2 5544 3.1 1.2 7715 3.1
High Organic (105%) Methanol) 1.98 1.1 5098 2.89 1.1 7432 2.8
Low Organic (95% Methanol) 2.7 1 5231 3.7 1 7654 3.7

Table 4: Robustness evaluation.

Filter validation and solution stability

Two different types of 0.45μm filters (Nylon and PVDF) were used to determine the filter’s effect on the sample. Concentrations of both types of filtered samples were calculated and compared against the centrifuged sample and showed no difference in results. The sample solution was stable for up to 24h on the bench.


A rapid, simple, reproducible, and robust reversed-phase HPLC method was developed and validated as per ICH guidelines for the determination of Albendazole and Levamisole in bulk and tablet dosage form. The method provides selective quantification of ALB+LEV mixture without interference of the blank and placebo. The proposed method will be readily adapted to the routine quality control analysis.


  1. Adediran OA, Uwalaka EC (2015) Effectiveness Evaluation of Levamisole, Albendazole, Ivermectin, and Vernoniaamygdalina in West African Dwarf Goats. J Parasitol Res. [Ref.]
  2. Gupta M (2016) Levamisole A multi-faceted drug in dermatology. Indian J Dermatol Venereol Leprol 82: 230-236. [Ref.]
  3. Keiser J, Tritten L, Adelfio R, Vargas M (2012) Effect of combinations of marketed human anthelmintic drugs against Trichuris muris in vitro and in vivo. Parasites Vectors 5: 292. [Ref.]
  4. Firozabad AR, Meybodi ZA, Mousavinasab SR, Sahebnasagh A, Jelodar MG, et al. (2021) Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial. BMC Infect Dis 21: 297. [Ref.]
  5. Runge LA, Pinals RS, Lourie SH, Tomar RH (1977) Treatment of rheumatoid arthritis with levamisole. A controlled trial. Arthritis Rheum 20: 1445-1448. [Ref.]
  6. Abdalla EE, Adam IJ, Blair GE, Boylston A, Sue-Ling HM, et al. (1995) The immunomodulatory effect of levamisole is influenced by postoperative changes and type of lymphocyte stimulant. Cancer Immunol Immunother 41: 193-198. [Ref.]
  7. Oladele OA, Emikpe BO, Adeyefa CAO, Enibe DF (2012) Effects of levamisole hydrochloride on cellular immune response and flock performance of commercial broilers. Rev Bras Cienc Avic 14: 259- 265. [Ref.]
  8. Indian Pharmacopoeia (2010) Govt of India, Ministry Of Health and Family Welfare, New Delhi 2: 1635-1636.
  9. Macha B, Nakkala K, Garige AK, RR Akkinepally, Garlapati A (2018) Synthesis and Evalution of New Tacrine Derivatives as Anti- Alzheimer’s Agents. Int J Pharm Biol Sci 8: 590-597. [Ref.]
  10. Nakkala K, Godiyal S, Laddha KS (2020) Isolation Of Starch From Curcuma Longa L and its Characterization. Int J Pharm Sci Res 11: 5712-5717. [Ref.]
  11. Council of Europe (2007) European Pharmacopoeia 6th Edition, Main Volume with Supplements 6.1 and 6.2. [Ref.]
  12. British Pharmacopoeia Commission, Stationery Office (2011) British Pharmacopoeia 2012. In: Te Department Of Health, Social Services and Public Safety. Stationery Office 2. [Ref.]
  13. Rockville (2001) United States pharmacopeia. United States Pharmacopeial Convention, Incorporated, Rockville, Md1141. [Ref.]
  14. Te British Pharmacopoeia (Veterinary) (2011) Her Majesty’s Stationary Office, London, UK, 91, 78.
  15. Te European Pharmacopoeia (2008) Te European Pharmacopoeia, Council of Europe, Strasbourg, 7th edition.
  16. Te United States pharmacopeia 34 (2011) NF 29, Asian Ed. Rand McNally, USA, 245, 3284.
  17. Stout SJ, daCunha AR, Tondreau RE, Boyd JE (1988) Confirmation of levamisole residues in cattle and swine livers by capillary gas chromatography-electron impact mass spectrometry. J Assoc Off Anal Chem 71: 1150-1153. [Ref.]
  18. Chappell CG, Creaser CS, Stygall JW, Shepherd MJ (1992) On-line high-performance liquid chromatographic/gas chromatographic/ tandem ion trap mass spectrometric determination of levamisole in milk. Biol Mass Spectrom 21: 688-692. [Ref.]
  19. Cherlet M, De Baere S, Croubels S, De Backer P (2000) Quantitative analysis of levamisole in porcine tissues by high-performance liquid chromatography combined with atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 742: 283-293. [Ref.]
  20. De Baere S, Cherlet M, Croubels S, Baert K, De Backer P (2003) Liquid chromatographic determination of levamisole in animal plasma Ultraviolet versus tandem mass spectrometric detection. Analytica Chimica Acta 483: 215-224. [Ref.]
  21. Jedziniak P, Szprengier-Juszkiewicz T, Olejnik M (2009) Determination of benzimidazoles and levamisole residues in milk by liquid chromatography-mass spectrometry: Screening method development and validation. J Chromatogr A 1216: 8165-8172. [Ref.]
  22. Tong L, Ding L, Li Y, Wang Z, Wang J, et al. (2011) A sensitive LCMS/ MS method for determination of levamisole in human plasma: Application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 879: 299-303. [Ref.]
  23. Xu J, Xiao S, Dong W, Sui K, Cao J, et al. (2012) Determination of levamisole residue in animal livers by two liquid-liquid extraction steps-gas chromatography-mass spectrometry. Chinese J Chromato 30: 922-925. [Ref.]
  24. Katakam LNR, Ettaboina SK, Marisetti VM (2021) Development and validation of LC-MS method for the determination of heptaethylene glycol monomethyl ether in benzonatate bulk drugs. Biomedical Chromatography. [Ref.]
  25. Marriner S, Galbraith EA, Bogan JA (1980) Determination of the anthelmintic levamisole in plasma and gastro-intestinal fluids by high-performance liquid chromatography. Analyst 105: 993-996. [Ref.]
  26. Katakam LNR, Dongala T, Ettaboina SK (2020) Novel stability indicating UHPLC method development and validation for simultaneous quantification of hydrocortisone acetate, pramoxine hydrochloride, potassium sorbate and sorbic acid in topical cream formulation. Talanta Open. [Ref.]
  27. Garcia JJ, Diez MJ, Sierra M, Teran MT (1990) Determination of Levamisole by HPLC in Plasma Samples in the Presence of Heparin and Pentobarbital. J Liquid Chromato 13: 743-749. [Ref.]
  28. Wyhowski de Bukanski B, Degroodt JM, Beernaert H (1991) Determination of levamisole and thiabendazole in meat by HPLC and photodiode array detection. Z Lebensm Unters Forsch 193: 545-547. [Ref.]
  29. Vandamme TF, Demoustier M, Rollmann B (1995) Quantitation of levamisole in plasma using high performance liquid chromatography. Eur J Drug Metab Pharmacokinet 20: 145-149.
  30. Du Preez JL, Lotter AP (1996) Solid-phase extraction and HPLC determination of levamisole hydrochloride in sheep plasma. Onderstepoort J Vet Res 63: 209-211. [Ref.]
  31. Dreassi E, Corbini G, La Rosa C, Politi N, Corti P (2001) Determination of levamisole in animal tissues using liquid chromatography with ultraviolet detection. J Agric Food Chem 49: 5702-5705. [Ref.]
  32. Katakam LNR, Ettaboina SK, Dongala T (2021) A simple and rapid HPLC method for determination of parabens and their degradation products in pharmaceutical dosage forms. Biomedical Chromatography. [Ref.]
  33. Katakam LNR, Dongala T, Ettaboina SK (2021) Quality by design with design of experiments approach for development of a stabilityindicating LC method for enzalutamide and its impurities in soft gel dosage formulation. Biomed Chromatogr 35. [Ref.]
  34. Sowjanya S, Devadasu C (2018) Development of RP-HPLC Method for the Simultaneous Quantitation of Levamisole and Albendazole: Application to Assay Validation. Int J Anal Chem. [Ref.]
  35. Patel PA, Prajapati AP, Luhar SV, Narkhede SB (2018) Stability Indicating Method Development and Validation for Simultaneous Estimation of Levamisole Hcl and Albendazole in Tablet Dosage Form. [Ref.]
  36. International Conference on Harmonization (2000) Stability Testing of New Drug Substances and Products. Geneva: ICH Q1A (R2). [Ref.]
  37. International Conference on Harmonization (2005) Validation of Analytical Procedures Text and Methodology. ICH Q2 (R1). [Ref.]

Download Provisional PDF Here


Article Information


Citation: Ettaboina SK, Nakkala K (2021) Development and Validation of New Analytical Methods for the Simultaneous Estimation of Levamisole and Albendazole in Bulk and Tablet Dosage Form by RP-HPLC. J Pharm Anal Insights 3(1):

Copyright: ©2021 Ettaboina SK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication history: 

  • Received date: 18 Jul, 2021

  • Accepted date: 20 Aug, 2021

  • Published date: 08 Sep, 2021